Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialAurore Perrot, Jill Corre, D. Caillot et al.|Blood|2025Cited by 34
Debulking Conventional Chemotherapy before Treatment By Anti-BCMA Bispecific Antibody in Extramedullary and/or High Tumor Burden Relapsed/Refractory Multiple MyelomaThomas Chalopin, Salomon Manier, Hélène Demarquette et al.|Blood|2024Cited by 3